Company intelligence / Profile preview
Traws Pharma, Inc.
Newtown, Pennsylvania, United Statestrawspharma.com ↗
- Ownership
- Public · TRAW
- Employees
- ~7
- Development stage
- Phase 1
01
Overview
Traws Pharma has advanced its lead antiviral program tivoxavir marboxil for bird flu into positive Phase 1 studies with robust preclinical efficacy in animal models against avian influenza and drug-resistant strains. Ratutrelvir for COVID targets Mpro without ritonavir co-administration and narazaciclib for oncology indications has entered Phase 1/2 trials in endometrial cancer[5][6].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
SymBio Pharmaceuticals LimitedPint International SAViriom, Inc.Temple University[3][4]
04
Financials
- Market cap
- $3.4M
- Total revenue
- $2.8M
- Enterprise value
- $249.6K
Beyond the preview
Go deeper on Traws Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Traws Pharma, Inc..